# The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The INRange RCT

Study · id `cardio:ct-nct02376803` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02376803](<https://clinicaltrials.gov/study/NCT02376803>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02376803

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 217 participants.

## Technical summary

Registry record NCT02376803. Randomized; no masking; primary purpose treatment. Start 2015-02 (registry gives no type); primary completion 2016-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 217 participants (enrolled count; ClinicalTrials.gov record NCT02376803, source copy `cardio:ctgov-nct02376803-2018-05-04`, retrieved 2026-10-26)
- Start date: 2015-02 (registry gives no type) (ClinicalTrials.gov record NCT02376803, source copy `cardio:ctgov-nct02376803-2018-05-04`, retrieved 2026-10-26)
- Primary completion: 2016-09-30 (actual) (ClinicalTrials.gov record NCT02376803, source copy `cardio:ctgov-nct02376803-2018-05-04`, retrieved 2026-10-26)
- Completion: 2018-04-27 (actual) (ClinicalTrials.gov record NCT02376803, source copy `cardio:ctgov-nct02376803-2018-05-04`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02376803, source copy `cardio:ctgov-nct02376803-2018-05-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02376803-2018-05-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT
- Condition: Atrial Fibrillation
- Condition: Thrombus Due to Heart Valve Prosthesis
- Condition: Deep Venous Thrombosis
- Condition: Thromboembolism
- Condition: DVT
- Intervention (Drug): Warfarin
- Lead sponsor: University of Alberta
- Lead sponsor class: OTHER
- Collaborator: Vancouver Coastal Health Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: University of Alberta (`cardio:org-university-of-alberta`)

## Provenance

Content hash: 25277468ab9888e7eb2f7e17eb487eaac852de121de739df77dacafa290266b6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
